Search for a networks
A phase Ia/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ALL, and other hematologic malignancies (coordination)
- Type of network : Multinational clinical trials
- Geographic coverage : Global
- Funding body(ies) : -
- Sponsor : Novartis international ag
Last update: July 2011
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.